Phase II randomized study of salvage radiation therapy plus enzalutamide or placebo for high-risk prostate-specific antigen recurrent prostate cancer after radical prostatectomy: the SALV-ENZA trial
Androgen receptor signaling inhibitors in addition to docetaxel with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis
Young age on starting prostate-specific antigen testing is associated with a greater reduction in prostate cancer mortality: 24-year follow-up of the Göteborg randomized population-based prostate cancer screening trial
Effect of positive surgical margins at radical prostatectomy on cancer-specific mortality in high/very high-risk prostate cancer patients with Gleason Grade Group 4–5
Prostate-specific antigen density cutoff of 0.15 ng/ml/cc to propose prostate biopsies to patients with negative magnetic resonance imaging: Efficient threshold or legacy of the past?
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study
Targeted multiparametric magnetic resonance imaging/ultrasound fusion biopsy for quantitative Gleason 4 rrading prediction in radical prostatectomy specimens: Implications for active surveillance candidate selection
Detection of clinically significant prostate cancer using targeted biopsy with four cores versus target saturation biopsy with nine cores in transperineal prostate fusion biopsy: A prospective randomized trial